RESEARCH ARTICLE

Prognostic significance of CT-determined sarcopenia in patients with advanced gastric cancer

Jong Soo Lee\(^{1}\)\(^{\‡}\), Young Saing Kim\(^{2}\)\(^{\‡}\), Eun Young Kim\(^{3}\)*, Wook Jin\(^{4}\)

1 School of Medicine, Gachon University School of Medicine, Incheon, South Korea, 2 Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea, 3 Department of Radiology, Gachon University Gil Medical Center, Incheon, South Korea, 4 Laboratory of Molecular Disease and Cell Regulation, Department of Biochemistry, Gachon University School of Medicine, Incheon, South Korea

☯ These authors contributed equally to this work.
‡ These authors share first authorship on this work.
* oneshot0229@gmail.com

Abstract

Background
Sarcopenia, defined as decreased skeletal muscle mass, is prevalent and associated with poor prognosis in various solid tumors. This study aimed to determine the prognostic role of sarcopenia in patients with advanced gastric cancer (AGC).

Methods
This retrospective study consisted of 140 consecutive patients who underwent palliative chemotherapy for AGC. A cross-sectional area of muscle at the level of the third lumbar vertebra (L3) was measured using baseline computed tomography (CT) scans. Sarcopenia was defined as a L3 skeletal muscle index of $49 \text{ cm}^2/\text{m}^2$ for men and $31 \text{ cm}^2/\text{m}^2$ for women using Korean-specific cutoffs. We compared the overall survival (OS) and clinical characteristics of patients with and without sarcopenia.

Results
The median age was 67 years, and 133 (95%) patients had metastatic disease. Sarcopenia was present in 67 patients (47.9%) and was significantly related to male sex ($p < 0.001$) and low body mass index ($p = 0.002$). Patients with sarcopenia had a significantly shorter OS than those without sarcopenia (median, 6.8 months vs. 10.3 months, respectively; $p = 0.033$). In the multivariable analysis, sarcopenia was an independent prognostic factor of poor OS (hazard ratio, 1.51, $p = 0.029$); no response to chemotherapy ($p < 0.001$), no second-line chemotherapy ($p < 0.001$), metastatic sites $\geq 3$ ($p < 0.001$), and low serum albumin level ($p = 0.033$) were also independent prognostic factors of poor OS.
Conclusion

Sarcopenia, as determined by baseline CT, can be used to predict poor prognosis in AGC patients treated with palliative chemotherapy.

Introduction

Stomach cancer is the second most common cancer and the third leading cause of cancer-related death in Korea [1]. Early stomach cancer can be cured by surgical resection [2]. Although early detection is often possible with screening, more than half of all patients are diagnosed with inoperable advanced or metastatic disease requiring palliative chemotherapy [3]. Weight loss, which is a key feature of cancer cachexia syndrome [4], is a common presentation in patients with advanced gastric cancer (AGC). However, weight loss may not always be accurately described by patients during medical examinations. In addition, body weight changes do not precisely reflect body composition changes. Moreover, weight loss is uncertain in patients with a large tumor mass or fluid collection, such as ascites or body edema.

Sarcopenia, defined by a loss of skeletal muscle mass, is an important age-related health issue in elderly people. It is associated with physical disability, injury, and mortality. Recently, the clinical significance of sarcopenia in patients with various forms of cancer is being increasingly recognized; sarcopenia is an independent prognostic factor associated with a decreased survival and an increased risk of chemotherapy toxicity in various forms of cancer, including small cell lung cancer, breast cancer, hepatocellular carcinoma, and urothelial cancer [5–10].

Although a previous Japanese cohort study revealed low skeletal muscle mass is not associated with poor prognosis in patients with metastatic gastric cancer receiving chemotherapy, the study used cut points derived from a Caucasian population [11]. The primary objective of this study was to evaluate the prognostic role of computed tomography (CT)-determined skeletal muscle index using ethnic specific cut-offs for sarcopenia in AGC patients receiving palliative chemotherapy.

Patients and methods

Patients

The medical records of consecutive patients diagnosed with AGC between January 2012 and December 2015 were screened using a prospectively maintained gastric cancer database. Among these patients, the selection criteria for analysis were as follows: patients who had histologically proven gastric cancer, underwent first-line palliative chemotherapy, and had adequate quality abdominopelvic (AP) CT scans within 4 weeks of initiation of first-line chemotherapy.

Clinicopathological data included age, sex, height, weight, Eastern Cooperative Oncology Group performance status (ECOG PS), human epidermal growth factor receptor 2 (HER2) status, baseline laboratory values (complete blood count with differential count and serum chemistry), disease status (locally advanced vs. metastatic), metastatic site, previous treatment history, chemotherapy regimen, chemotherapy response, survival status, and dates of administration of chemotherapy and the last follow-up. Response evaluation was performed according to the Response Evaluation Criteria in Solid Tumors version 1.1 using follow-up radiographic images obtained every 6 to 8 weeks during treatment.

Body mass index (BMI) was calculated as weight divided by height squared (kg/m²), and BMI values were categorized as underweight (< 18.5 kg/m²), normal (18.5–22.9 kg/m²), overweight (23.0–24.9 kg/m²), or obese (≥ 25 kg/m²) [12].
Ethics approval for this study was granted by the Gil Medical Center Institutional Review Board (approval number: GBIRB-2017-218).

Image analysis
CT images from AP CT scans were retrospectively analyzed by a radiologist (EYK) who is blinded to clinical outcome of the patients. The third lumbar vertebra (L3) was selected as the landmark since the cross-sectional area of skeletal muscle mass in this region was found to be most correlated with total body SMM ($r = 0.924$, $p < 0.001$) in the general population [13–15].

To quantify skeletal muscle mass using AP CT, commercially available software (Terarecon version 3.4.2.11, San Mateo, CA) was used. After applying threshold methods using a pre-defined Hounsfield unit (HU) threshold of -25 to 150 HU for skeletal muscle mass, muscle boundaries were corrected manually when necessary to obtain cross-sectional areas (cm$^2$) for skeletal muscle. L3 skeletal muscle index (SMI, cm$^2$/m$^2$) was defined as the cross-sectional area of muscle at the L3 level normalized for stature as is conventional for BMI.

Definition of sarcopenia
Sarcopenia was defined as a L3 SMI of $\leq 49$ cm$^2$/m$^2$ for men and $\leq 31$ cm$^2$/m$^2$ for women using cutoff points specific for the Korean population, based on the Korea National Health and Nutrition Examination Study (KNHANES). A previous epidemiologic study evaluated height-adjusted appendicular skeletal muscle mass (ASM; kg/m$^2$) of a reference group of young Koreans using dual-energy X-ray absorptiometry (DXA) and determined sarcopenia cutoff values of 6.58 and 4.59 kg/m$^2$ for Korean men and women, respectively [16]. It was reported that L3 muscle area by CT and ASM by DXA are linearly related; L3 SMI cutoff values were calculated using the regression equation [13]:

$$L3 \text{ SMI (cm}^2/\text{m}^2) = \frac{\text{[height-adjusted ASM (kg/m}^2) - 1.17]}{0.11}.$$

Statistical analysis
Descriptive statistics were reported as proportions or medians with ranges. Comparisons between subjects with and without sarcopenia were performed using Pearson’s $\chi^2$ test or Fisher’s exact test for categorical variables. Continuous variables were analyzed using Student’s $t$-test or the Mann–Whitney U test. Survivals were estimated using the Kaplan–Meier method and compared using the log-rank test. Overall survival (OS) was defined as the time from the date of initiation of first-line chemotherapy to the date of death or last follow-up. Multivariable Cox proportional hazard models were used to identify prognostic factors for survival. Variables with a p-value of < 0.05 by the log-rank test were included in the multivariable analysis, and backward regression was used. Two-sided p-values < 0.05 were considered statistically significant. The analysis was performed using the open-source statistical software R version 3.3.1 (R Foundation, Vienna, Austria, http://www.r-project.org).

Results
Characteristics of the study population
A total of 140 consecutive patients were included in this study (Table 1). Among them, 106 patients (75.7%) were male, and 133 (95.0%) had metastatic disease. Forty-eight patients (34.3%) were HER2-positive. The average BMI was $21.4 \pm 3.3$ kg/m$^2$ and 22.9% of the patients were underweight ($n = 32$). The mean L3 SMI was $46.6 \pm 9.1$ cm$^2$/m$^2$ (range: 16.1–72.6 cm$^2$/m$^2$) for men and $38.7 \pm 5.1$ cm$^2$/m$^2$ (range: 30.5–49.5 cm$^2$/m$^2$) for women.
Table 1. Patient characteristics according to the presence of sarcopenia.

| Characteristics                                | Sarcopenia (n = 67) | No sarcopenia (n = 73) | p value |
|------------------------------------------------|---------------------|------------------------|---------|
| Age (years) Median (range)                      | 69 (29–83)          | 66 (22–91)             | 0.061   |
| ≥ 70 years                                      | 32 (47.8%)          | 25 (34.2%)             | 0.104   |
| Male                                           | 66 (98.5%)          | 40 (54.8%)             | <0.001  |
| Extent of disease                               |                     |                        | 0.786   |
| Locally advanced                                | 3 (4.5%)            | 4 (5.5%)               |         |
| Metastatic                                      | 64 (95.5%)          | 69 (94.5%)             |         |
| ECOG performance status                         |                     |                        | 0.271   |
| 0–1                                            | 51 (76.1%)          | 60 (83.6%)             |         |
| ≥ 2                                            | 16 (23.9%)          | 12 (16.4%)             |         |
| HER2(+)                                         | 22 (32.8%)          | 26 (35.6%)             | 0.729   |
| First-line regimen                              |                     |                        | 0.968   |
| S-1/cisplatin or XP                             | 20 (29.9%)          | 22 (30.1%)             |         |
| FOLFOX or XELOX                                 | 17 (25.4%)          | 16 (21.9%)             |         |
| Trastuzumab plus XP                             | 12 (17.9%)          | 16 (21.9%)             |         |
| FOLFIRI                                         | 3 (4.5%)            | 5 (6.8%)               |         |
| Modified DCF                                    | 3 (4.5%)            | 2 (2.7%)               |         |
| Trastuzumab plus capecitabine                   | 9 (13.4%)           | 10 (13.7%)             |         |
| S-1 or capecitabine                             | 3 (4.5%)            | 2 (2.7%)               |         |
| Response to first-line therapy                  |                     |                        | 0.363   |
| Responder                                       | 27 (40.3%)          | 35 (47.9%)             |         |
| Non-responder                                   | 40 (59.7%)          | 38 (52.1%)             |         |
| Receipt of second-line therapy                  |                     |                        | 0.102   |
| 23 (34.3%)                                      | 35 (47.9%)          |                         |         |
| Second-line regimen 1                           | 0.454               |                        |         |
| Paclitaxel                                      | 9 (39.1%)           | 15 (42.9%)             |         |
| Irinotecan                                      | 6 (26.1%)           | 7 (20.0%)              |         |
| FOLFIRI                                         | 2 (8.7%)            | 8 (22.9%)              |         |
| FOLFOX                                          | 2 (8.7%)            | 3 (8.6%)               |         |
| Ramucirumab plus paclitaxel                     | 2 (8.7%)            | 2 (5.7%)               |         |
| Docetaxel                                       | 2 (8.7%)            | 0                      |         |
| Number of metastatic sites                      | 0.576               |                        |         |
| ≥ 2                                            | 54 (80.6%)          | 56 (76.7%)             |         |
| ≥ 3                                            | 13 (19.4%)          | 17 (23.3%)             |         |
| BMI                                             |                     |                        | 0.002   |
| Underweight                                     | 23 (34.3%)          | 9 (12.3%)              |         |
| Normal                                          | 29 (43.3%)          | 31 (42.5%)             |         |
| Overweight                                      | 12 (17.9%)          | 18 (24.7%)             |         |
| Obese                                           | 3 (4.5%)            | 15 (20.5%)             |         |
| L3 SMI (cm²/m²), median (range)                 | 42.4 (16.1–48.7)    | 49.8 (31.9–72.6)       | <0.001  |
| Hemoglobin (g/dL), median (range)               | 10.2 (7.2–15.0)     | 11.2 (7.2–15.8)        | 0.082   |
| Serum albumin (g/dL)                            |                      |                        |         |
| median (range)                                  | 3.4 (2.4–4.5)       | 3.6 (1.9–4.5)          | 0.114   |
| < 3.5 g/dL                                      | 33 (49.3%)          | 24 (32.9%)             | 0.072   |
| Neutrophil-lymphocyte ratio, median (range)     | 3.8 (1.1–45.6)      | 3.0 (1.0–22.3)         | 0.085   |

(Continued)
Prevalence of and factors associated with sarcopenia

The overall prevalence of sarcopenia was 47.9% (62.3% for men and 2.9% for women). In elderly patients (aged ≥ 70 years), the overall prevalence of sarcopenia was 56.1% (90.0% for men and 0% for women). The clinical characteristics of patients with and without sarcopenia are summarized in Table 1. The prevalence of sarcopenia was related to male sex (p < 0.001) and low BMI (p = 0.002). No significant difference was found between patients with and without sarcopenia regarding age, the extent of the disease, ECOG PS, HER2 status, first-line regimen, response to chemotherapy, receipt of second-line therapy, number of metastatic sites, hemoglobin level, serum albumin level, neutrophil to lymphocyte ratio, and C-reactive protein level.

Prognostic significance of sarcopenia in AGC patients

Over a median follow-up of 31.9 months (95% confidence interval [CI]: 28.8–34.9 months), 124 patients (88.6%) died. For all patients, the median OS was 8.6 months (95% CI, 6.7–10.4 months). Patients with sarcopenia had a significantly shorter median OS than those without sarcopenia (6.8 vs. 10.3 months, respectively; p = 0.033 by the log-rank test; Fig 1).

Univariable analysis showed that in addition to the presence of sarcopenia, ECOG PS ≥ 2, no response to chemotherapy, no second-line chemotherapy, low serum albumin level (< 3.5 g/dL), and metastatic sites ≥ 3 were significant prognostic factors (Table 2). Multivariable analysis showed that sarcopenia was an independent prognostic factor for a shorter OS (hazard ratio [HR], 1.51; 95% CI, 1.04–2.18; p = 0.029), along with no response to chemotherapy (HR, 2.47; 95% CI, 1.69–3.61; p < 0.001), no second-line chemotherapy (HR, 2.43; 95% CI, 1.64–3.59, p < 0.001), metastatic sites ≥ 3 (HR, 2.31; 95% CI, 1.49–3.60; p < 0.001), and low serum albumin level (HR, 1.50; 95% CI, 1.03–2.19; p = 0.033).

Discussion

Sarcopenia, characterized by progressive and generalized loss of skeletal muscle mass [17], has been established as a key diagnostic criterion for cancer cachexia [4]. CT is regarded as the gold-standard method to evaluate body composition and the presence of sarcopenia [18]; it is also a useful tool for staging and response assessment of gastric cancer. Using baseline CT scans before palliative chemotherapy, we showed that sarcopenia is commonly present in patients with AGC (47.9%). Moreover, sarcopenia was identified as an independent prognostic factor for a poor OS.

The significance of sarcopenia in the management of gastric cancer has been analyzed mainly in patients who underwent gastrectomy. In previous studies including more than 100 patients individually, the prevalence of preoperative sarcopenia ranged from 12.5% to 57.7%...
Sarcopenia negatively affects the surgical treatment of stomach cancer patients. It is an independent risk factor for postoperative complications in patients undergoing radical gastrectomy [19, 22, 23, 25, 26] and patients with sarcopenia had a significantly shorter OS after surgery [20, 22, 27, 28]. Moreover, sarcopenia was associated with chemotherapy toxicity in gastric cancer patients in the perioperative setting, leading to early discontinuation of chemotherapy and dose reduction [29, 30]. At palliative setting of gastric cancer, a Japanese cohort study revealed low skeletal muscle mass is not associated with poor prognosis [11]. However, the sample size was small (n = 53) and they used skeletal muscle index cut points derived from a Caucasian population to determine sarcopenia, which would be inappropriate for Asian population. In the study, low skeletal muscle density caused by increase in lipid content of muscle was an independent predictor of poor outcome, which would indicate the muscle quality change precede the quantity change.

The diagnostic criteria of sarcopenia remain controversial and cutoff values, used for defining sarcopenia, differed between studies. The cutoffs for L3 SMI to define sarcopenia in gastric cancer ranged from 36.0 to 53.0 cm$^2$/m$^2$ in men and from 29.0 to 41.0 cm$^2$/m$^2$ in...
women [19–25]. The European Working Group on Sarcopenia in Older People recommends the use of data from healthy young adults, with cutoff points at two standard deviations below the mean reference value [17]. Therefore, the definition of sarcopenia can vary depending on the characteristics of the reference population, such as age, race, and country. The SMI cut-off as recommended by cancer cachexia consensus is 55.4 cm$^2$/m$^2$ for men and 38.9 cm$^2$/m$^2$ for women, which is based on data from 229 non-Hispanic white men and women aged 18 to 40 years who were participants in the Rosetta Study (1986–1992) [31, 32]. In contrast, we used Korean-specific diagnostic criteria for sarcopenia: individuals aged 20 to 29 years (1,047 men and 1,433 women) who participated in KNHANES (2008–2010) were used as the young reference group to determine the sarcopenia cutoff points [33]. More research is needed to obtain good reference values for various ethnic groups and cancer patients.

In this study, sarcopenia appears to be dramatically more prevalent in men compared with women (62.3% vs. 2.9%). This would reflect ethnic characteristics of the extremely low prevalence of sarcopenia in Korean women. A recent epidemiologic study reported extremely low prevalence of sarcopenia in Korean women (prevalence of sarcopenia, 12.4% vs 0.1% for elderly men and women in Korean population of ≥ 65 years) [16], in comparison with similar prevalence of sarcopenia between sex in Western countries (prevalence of sarcopenia for elderly men and women, 25.7% and 23.1% in Germany [34], 26.8% and 22.6% in America [35]).

There are several potential explanations for the relationship between sarcopenia and poor prognosis in patients with advanced cancer. First, tumors with a more aggressive behavior tend to have a higher metabolic activity that may lead to sarcopenia [36]. However, we found no difference in the response to chemotherapy between patients with and without sarcopenia (p = 0.583). Second, several studies have suggested that myokines, hormones produced by skeletal muscle, may have anticancer effects [37, 38]. Therefore, the decrease in myokine secretion due to muscle loss may be related to cancer progression. Third, poor tolerance to chemotherapy can explain the negative effects of sarcopenia on survival [29, 30].

Previous study revealed muscle loss of more than 9% during chemotherapy was also independently associated with a shorter survival (HR, 4.47; 95% CI, 2.21–9.05; p < 0.001) [39]. This finding suggests that interventions to prevent sarcopenia or to increase muscle mass may be a potential therapeutic strategy to improve treatment outcomes in cancer patients.
exercise, specifically resistance training, can increase muscle mass and strength in people with age-related sarcopenia [40, 41]. Recent studies have evaluated exercise interventions (aerobic or resistance exercise, or both) in advanced cancer patients, and have suggested that supervised exercise interventions are safe and feasible [42]. In addition, it was reported that exercise interventions can maintain or improve muscle strength and physical function and may improve quality of life in advanced cancer patients [43]. Future research should aim to implement large, long-term, randomized trials to investigate the effects of exercise on mortality in advanced cancer. Studies on the effects of a combination of exercise and pharmacologic agents should also be performed. Currently, a phase III trial of multimodal intervention (exercise, nutrition, anti-inflammatory medication) is being conducted across a number of international sites (NCT02330926) [44].

The present study has several limitations that require consideration. First, the patients’ number was small because this study was performed at a single institution. Second, we failed to get information regarding muscle function and body weight changes as a retrospective study design. Third, we did not evaluate the skeletal muscle density, although several studies have suggested that the skeletal muscle density may be superior to muscle mass in predicting survival [11, 45–47]. Further study is needed to evaluate the usefulness of these imaging biomarkers in detecting and monitoring sarcopenia.

In summary, sarcopenia, as determined by baseline CT, can be used to predict prognosis in patients with AGC who are under treatment with palliative chemotherapy. The identification of sarcopenia in AGC patients may enable early intervention to maintain and improve muscle mass. Further research is required to determine whether various therapies, including exercise for preventing sarcopenia, can improve the prognosis of cancer patients.

Author Contributions

Conceptualization: Young Saing Kim, Eun Young Kim.

Formal analysis: Jong Soo Lee, Young Saing Kim, Eun Young Kim.

Funding acquisition: Young Saing Kim.

Methodology: Young Saing Kim.

Resources: Young Saing Kim, Eun Young Kim.

Supervision: Eun Young Kim.

Visualization: Jong Soo Lee.

Writing – original draft: Jong Soo Lee.

Writing – review & editing: Young Saing Kim, Eun Young Kim, Wook Jin.

References

1. Oh CM, Won YJ, Jung KW, Kong HJ, Cho H, Lee JK, et al. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2013. Cancer Res Treat. 2016; 48(2):436–50. Epub 2016/03/19. https://doi.org/10.4143/crt.2016.089 PMID: 26987395; PubMed Central PMCID: PMCPMC4843732.

2. Thrumurthy SG, Chaudry MA, Hochhauser D, Mughal M. The diagnosis and management of gastric cancer. BMJ (Clinical research ed). 2013; 347:f6367. Epub 2013/11/06. https://doi.org/10.1136/bmj.f6367 PMID: 24191271.

3. Wohrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann Oncol. 2004; 15(11):1565–9. Epub 2004/11/03. https://doi.org/10.1093/annonc/mdh422 PMID: 15520058.

4. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. The Lancet Oncology. 2011; 12(5):489–95. Epub 2011/02/08. https://doi.org/10.1016/S1470-2045(10)70218-7 PMID: 21296615.
5. Fukushima H, Yokoyama M, Nakanishi Y, Tobisu K, Koga F. Sarcopenia as a prognostic biomarker of advanced urothelial carcinoma. PLoS One. 2015; 10(1):e0115895. Epub 2015/01/23. https://doi.org/10.1371/journal.pone.0115895 PMID: 25612215; PubMed Central PMCID: PMCPMC4303429.

6. Harimoto N, Shirabe K, Yamashita YI, Ikegami T, Yoshizumi T, Soejima Y, et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. Br J Surg. 2013; 100(11):1523–30. Epub 2013/09/17. https://doi.org/10.1002/bjs.9258 PMID: 24037576.

7. Huillard O, Mir O, Peyromaure M, Tlemsani C, Giroux J, Boudou-Rouquette P, et al. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer. 2013; 108(5):1034–41. Epub 2013/03/07. https://doi.org/10.1038/bjc.2013.58 PMID: 23462722; PubMed Central PMCID: PMCPMC3619075.

8. Meza-Junco J, Montano-Loza AJ, Baracos VE, Prado CM, Bain VG, Beaumont C, et al. Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J Clin Gastroenterol. 2013; 47(10):861–70. Epub 2013/06/12. https://doi.org/10.1097/MCG.0b013e318293ab25 PMID: 23751844.

9. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009; 15(8):2920–6. Epub 2009/04/09. https://doi.org/10.1158/1078-0432.CCR-08-2242 PMID: 19351764.

10. Villasenor A, Ballard-Barbash R, Baumgartner K, Baumgartner R, Bernstein L, McTiernan A, et al. Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study. J Cancer Surviv. 2012; 6(4):398–406. Epub 2012/10/12. https://doi.org/10.1002/jcancer.20394 PMID: 23054848; PubMed Central PMCID: PMCPMC3747827.

11. Hayashi N, Ando Y, Gyawali B, Shimokata T, Maeda O, Fukaya M, et al. Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer. Oncology reports. 2016; 35(3):1727–31. Epub 2015/12/10. https://doi.org/10.3892/or.2015.4475 PMID: 26648321.

12. Consultation WHOE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004; 363(9403):157–63. Epub 2004/01/17. https://doi.org/10.1016/S0140-6736(03)15268-3 PMID: 14726171.

13. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008; 33(5):997–1006. Epub 2008/10/17. https://doi.org/10.1139/H08-075 PMID: 18923576.

14. Song MY, Ruts E, Kim J, Janumala I, Heymsfield S, Gallagher D. Sarcopenia and increased adipose tissue infiltration of muscle in elderly African American women. Am J Clin Nutr. 2004; 79(5):874–80. Epub 2004/04/29. https://doi.org/10.1093/ajcn/79.5.874 PMID: 15113728.

15. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. Journal of applied physiology (Bethesda, Md: 1985). 2004; 97(6):2333–8. https://doi.org/10.1152/japplphysiol.00744.2004 PMID: 15310748.

16. Kim YS, Lee Y, Chung YS, Lee DJ, Joo NS, Hong D, et al. Prevalence of sarcopenia and sarcopenic obesity in the Korean population based on the Fourth Korean National Health and Nutritional Examination Surveys. J Gerontol A Biol Sci Med Sci. 2012; 67(10):1107–13. Epub 2012/03/21. https://doi.org/10.1093/gerona/gls071 PMID: 22431554.

17. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age and ageing. 2010; 39(4):412–23. Epub 2010/04/16. https://doi.org/10.1093/ageing/afq034 PMID: 20393703; PubMed Central PMCID: PMCPMC2886201.

18. Aebli van Kan G, Houles M, Vellas B. Identifying sarcopenia. Current opinion in clinical nutrition and metabolic care. 2012; 15(5):436–41. Epub 2012/07/17. https://doi.org/10.1097/MCO.0b013e328356bbf4 PMID: 22795727.

19. Zhou CJ, Zhang FM, Zhang FY, Yu Z, Chen XL, Shen X, et al. Sarcopenia: a new predictor of postoperative complications for elderly gastric cancer patients who underwent radical gastrectomy. The Journal of surgical research. 2017; 211:137–46. Epub 2017/05/16. https://doi.org/10.1016/j.jss.2016.12.014 PMID: 28501109.

20. Kudou K, Saeki H, Nakashima Y, Edahiro K, Kurehisa S, Taniguchi D, et al. Prognostic Significance of Sarcopenia in Patients with Esophageogastric Junction Cancer or Upper Gastric Cancer. Annals of surgical oncology. 2017; 24(7):1804–10. Epub 2017/02/23. https://doi.org/10.1245/s10434-017-5811-9 PMID: 28224363.
21. Huang DD, Zhou CJ, Wang SL, Mao ST, Zhou XY, Lou N, et al. Impact of different sarcopenia stages on the postoperative outcomes after radical gastrectomy for gastric cancer. Surgery. 2017; 161(3):680–93. Epub 2016/10/08. https://doi.org/10.1016/j.surg.2016.08.030 PMID: 27712873.

22. Zhuang CL, Huang DD, Pang WY, Zhou CJ, Wang SL, Lou N, et al. Sarcopenia is an Independent Predictor of Severe Postoperative Complications and Long-Term Survival After Radical Gastrectomy for Gastric Cancer: Analysis from a Large-Scale Cohort. Medicine. 2016; 95(13):e3164. Epub 2016/04/05. https://doi.org/10.1097/MD.0000000000003164 PMID: 27043677; PubMed Central PMCID: PMC54998538.

23. Wang SL, Zhuang CL, Huang DD, Pang WY, Lou N, Chen FF, et al. Sarcopenia Adversely Impacts Postoperative Clinical Outcomes Following Gastrectomy in Patients with Gastric Cancer: A Prospective Study. Annals of surgical oncology. 2016; 23(2):556–64. Epub 2015/12/17. https://doi.org/10.1245/s10434-015-4887-3 PMID: 26668085.

24. Tegels JJ, van Vugt JL, Reisinger KW, Hulsewijk AG, Derikx JP, et al. Sarcopenia is highly prevalent in patients undergoing surgery for gastric cancer but not associated with worse outcomes. Journal of surgical oncology. 2015; 112(4):403–7. Epub 2015/09/04. https://doi.org/10.1002/jso.24015 PMID: 26331988.

25. Nishigori T, Tsunoda S, Okabe H, Tanaka E, Hisamori S, Hosogi H, et al. Impact of Sarcopenic Obesity on Surgical Site Infection after Laparoscopic Total Gastrectomy. Annals of surgical oncology. 2016; 23 (Suppl 4):524–31. Epub 2016/07/07. https://doi.org/10.1245/s10434-016-5348-y PMID: 27380646.

26. Chen FF, Zhang FY, Zhou XY, Shen X, Yu Z, Zhuang CL. Role of frailty and nutritional status in predicting complications following total gastrectomy with D2 lymphadenectomy in patients with gastric cancer: a prospective study. Langenbeck's archives of surgery. 2016; 401(6):813–22. Epub 2016/08/04. https://doi.org/10.1007/s00423-016-1490-4 PMID: 27485549.

27. Zheng ZF, Lu J, Zheng CH, Li P, Xie JW, Wang JB, et al. A Novel Prognostic Scoring System Based on Preoperative Sarcopenia Predicts the Long-Term Outcome for Patients After R0 Resection for Gastric Cancer: Experiences of a High-Volume Center. Annals of surgical oncology. 2017; 24(7):1795–803. Epub 2017/02/19. https://doi.org/10.1245/s10434-017-5813-7 PMID: 28213789.

28. Huang DD, Chen XX, Chen XY, Wang SL, Shen X, Chen XL, et al. Sarcopenia predicts 1-year mortality in elderly patients undergoing curative gastrectomy for gastric cancer: a prospective study. Journal of cancer research and clinical oncology. 2016; 142(11):2347–56. Epub 2016/08/31. https://doi.org/10.1007/s00432-016-2230-4 PMID: 27573385.

29. Palmela C, Velho S, Agostinho L, Branco F, Santos M, Santos MP, et al. Body Composition as a Prognostic Factor of Neoadjuvant Chemotherapy Toxicity and Outcome in Patients with Locally Advanced Gastric Cancer. Journal of gastric cancer. 2017; 17(1):74–87. Epub 2017/03/25. https://doi.org/10.5230/jgc.2017.17.e8 PMID: 28337365; PubMed Central PMCID: PMCPMC5362836.

30. Tan BH, Brammer K, Randhawa N, Welch NT, Parsons SL, James EJ, et al. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. European journal of surgical oncology: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2015; 41(3):333–8. Epub 2014/12/17. https://doi.org/10.1016/j.ejso.2014.11.040 PMID: 25498359.

31. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. American journal of epidemiology. 1998; 147(8):755–63. Epub 1998/04/29. PMID: 9554417.

32. Fearon KC. Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer. 2008; 44(8):1124–32. https://doi.org/10.1016/j.ejca.2008.02.033 PMID: 18375115.

33. Kim KM, Lim S, Choi SH, Kim JH, Shin CS, Park KS, et al. Cardiometabolic implication of sarcopenia: The Korea National Health and Nutrition Examination Study (KNHANES) 2008–2010. IJC Metabolic & Endocrine. 2014; 4:63–9. https://doi.org/10.1016/j.jcem.2014.06.001.

34. Spira D, Norman K, Nikolov J, Demuth I, Steinhagen-Thiessen E, Eckardt R. Prevalence and definition of sarcopenia in community dwelling older people: Data from the Berlin aging study II (BASE-II). Zeitschrift fur Gerontologie und Geriatrie. 2015. https://doi.org/10.1016/j.jcme.2014.11.040 PMID: 25877773.

35. Iannuzzi-Sucich M, Prestwood KM, Kenny AM. Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women. J Gerontol A Biol Sci Med Sci. 2002; 57(12):M772–7. PMID: 12456735.

36. Dodson S, Baracos VE, Jatoi A, Evans WJ, Cella D, Dalton JT, et al. Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. Annual review of medicine. 2011; 62:265–79. Epub 2010/08/25. https://doi.org/10.1146/annurev-med-061509-131246 PMID: 20731602.
37. Hojman P, Dethlefsen C, Brandt C, Hansen J, Pedersen L, Pedersen BK. Exercise-induced muscle-derived cytokines inhibit mammary cancer cell growth. American journal of physiology Endocrinology and metabolism. 2011; 301(3):E504–10. Epub 2011/06/10. https://doi.org/10.1152/ajpendo.00520.2010 PMID: 21653222.

38. Aoi W, Naito Y, Takagi T, Tanimura Y, Takanami Y, Kawai Y, et al. A novel myokine, secreted protein acidic and rich in cysteine (SPARC), suppresses colon tumorigenesis via regular exercise. Gut. 2013; 62(6):882–9. Epub 2012/08/02. https://doi.org/10.1136/gutjnl-2011-300776 PMID: 22851666.

39. Blauwhoff-Buskermolens S, Versteeg KS, de van der Schueren MA, den Braver NR, Berkhof J, Langius JA, et al. Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2016; 34(12):1339–44. Epub 2016/02/24. https://doi.org/10.1200/jco.2015.63.6043 PMID: 26993572.

40. Peterson MD, Sen A, Gordon PM. Influence of resistance exercise on lean body mass in aging adults: a meta-analysis. Medicine and science in sports and exercise. 2011; 43(2):249–58. Epub 2010/06/15. https://doi.org/10.1249/MSS.0b013e3181eb6265 PMID: 20543750; PubMed Central PMCID: PMCPMC2995836.

41. Peterson MD, Rhea MR, Sen A, Gordon PM. Resistance exercise for muscular strength in older adults: a meta-analysis. Ageing research reviews. 2010; 9(3):226–37. Epub 2010/04/14. https://doi.org/10.1016/j.arr.2010.03.004; PubMed Central PMCID: PMCPMC2892859.

42. Heywood R, McCarthy AL, Skinner TL. Safety and feasibility of exercise interventions in patients with advanced cancer: a systematic review. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer. 2017. Epub 2017/07/26. https://doi.org/10.1007/s00520-017-3827-0 PMID: 28741176.

43. Dittus KL, Gramling RE, Ades PA. Exercise interventions for individuals with advanced cancer: A systematic review. Preventive medicine. 2017; 104:124–32. Epub 2017/07/19. https://doi.org/10.1016/j.ymped.2017.07.015 PMID: 28716654.

44. Solheim TS, Laird BJA, Balstad TR, Bye A, Stene G, Baracos V, et al. Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial. BMJ supportive & palliative care. 2018. Epub 2018/02/02. https://doi.org/10.1136/bmjspcare-2017-001440 PMID: 29440149.

45. Sjoblom B, Gronberg BH, Wentzel-Larsen T, Baracos VE, Hjermstad MJ, Aass N, et al. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. Clinical nutrition (Edinburgh, Scotland). 2016; 35(6):1386–93. Epub 2016/04/23. https://doi.org/10.1016/j.clnu.2016.03.010 PMID: 27102408.

46. Antoun S, Laney E, Iacovelli R, Albigeas-Sauvin L, Loriot Y, Merad-Taoufik M, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer. 2013; 119(18):3377–84. Epub 2013/06/27. https://doi.org/10.1002/cncr.28218 PMID: 23801109.

47. Miller BS, Ignatowski KM, Daignault S, Lindland C, Doherty M, Gauger PG, et al. Worsening central sarcopenia and increasing intra-abdominal fat correlate with decreased survival in patients with adrenocortical carcinoma. World journal of surgery. 2012; 36(7):1509–16. Epub 2012/04/25. https://doi.org/10.1007/s00268-012-1581-5 PMID: 22526034.